当前位置:
X-MOL 学术
›
Eur. Heart J.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Routine Extracorporeal Life Support in Infarct-Related Cardiogenic Shock: 1-Year Results of the ECLS-SHOCK Trial
European Heart Journal ( IF 37.6 ) Pub Date : 2024-09-02 , DOI: 10.1093/eurheartj/ehae610 Steffen Desch 1 , Uwe Zeymer 2, 3 , Ibrahim Akin 4 , Michael Behnes 4 , Daniel Duerschmied 4 , Tienush Rassaf 5 , Amir Abbas Mahabadi 5 , Ralf Lehmann 6 , Ingo Eitel 7 , Tobias Graf 7 , Tim Seidler 8 , Andreas Schuster 8 , Tharusan Thevathasan 9 , Carsten Skurk 9 , Peter Clemmensen 10 , Marcus Hennersdorf 11 , Stephan Fichtlscherer 12 , Ingo Voigt 13 , Melchior Seyfarth 14 , Stefan John 15 , Sebastian Ewen 16 , Axel Linke 17 , Eike Tigges 18 , Peter Nordbeck 19 , Leonhard Bruch 20 , Christian Jung 21 , Jutta Franz 22 , Philipp Lauten 23 , Marko Noc 24 , Georg Fuernau 25 , Hans-Josef Feistritzer 1 , Janine Pöss 1 , Eva Kirchhof 26 , Taoufik Ouarrak 2 , Steffen Schneider 2 , Anne Freund 1 , Holger Thiele 1
European Heart Journal ( IF 37.6 ) Pub Date : 2024-09-02 , DOI: 10.1093/eurheartj/ehae610 Steffen Desch 1 , Uwe Zeymer 2, 3 , Ibrahim Akin 4 , Michael Behnes 4 , Daniel Duerschmied 4 , Tienush Rassaf 5 , Amir Abbas Mahabadi 5 , Ralf Lehmann 6 , Ingo Eitel 7 , Tobias Graf 7 , Tim Seidler 8 , Andreas Schuster 8 , Tharusan Thevathasan 9 , Carsten Skurk 9 , Peter Clemmensen 10 , Marcus Hennersdorf 11 , Stephan Fichtlscherer 12 , Ingo Voigt 13 , Melchior Seyfarth 14 , Stefan John 15 , Sebastian Ewen 16 , Axel Linke 17 , Eike Tigges 18 , Peter Nordbeck 19 , Leonhard Bruch 20 , Christian Jung 21 , Jutta Franz 22 , Philipp Lauten 23 , Marko Noc 24 , Georg Fuernau 25 , Hans-Josef Feistritzer 1 , Janine Pöss 1 , Eva Kirchhof 26 , Taoufik Ouarrak 2 , Steffen Schneider 2 , Anne Freund 1 , Holger Thiele 1
Affiliation
Extracorporeal life support (ECLS) has been increasingly used in the treatment of severe infarct-related cardiogenic shock in the last decade. The randomised ECLS-SHOCK trial demonstrated no benefit of early routine use on 30-day all-cause death. We herein present mid-term results. At 1-year follow-up, there were no significant differences in all-cause or cardiovascular mortality, neurologic outcome, recurrent myocardial infarction, repeat revascularisation and rehospitalisations for heart failure between ECLS and usual medical care.
中文翻译:
梗死相关心源性休克的常规体外生命支持:ECLS-SHOCK 试验的 1 年结果
在过去十年中,体外生命支持 (ECLS) 越来越多地用于治疗严重的梗死相关心源性休克。随机 ECLS-SHOCK 试验表明,早期常规使用对 30 天全因死亡没有益处。我们在此介绍中期结果。在 1 年随访中,ECLS 与常规医疗护理在全因或心血管死亡率、神经系统结局、复发性心肌梗死、重复血运重建和心力衰竭再住院方面没有显著差异。
更新日期:2024-09-02
中文翻译:
梗死相关心源性休克的常规体外生命支持:ECLS-SHOCK 试验的 1 年结果
在过去十年中,体外生命支持 (ECLS) 越来越多地用于治疗严重的梗死相关心源性休克。随机 ECLS-SHOCK 试验表明,早期常规使用对 30 天全因死亡没有益处。我们在此介绍中期结果。在 1 年随访中,ECLS 与常规医疗护理在全因或心血管死亡率、神经系统结局、复发性心肌梗死、重复血运重建和心力衰竭再住院方面没有显著差异。